Taiwan sets up fund for international biotech expertise
This article was originally published in Clinica
Taiwan is to establish a biotechnology fund to invest in the latest technologies from the US, Canada and Europe. Some NT$1.1 billion ($34.3 million) will be raised by various government agencies and private companies and at least 10 new key technologies are expected to be transferred to Taiwan in the next five years, the China Economic News Service reports.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.